DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. METHODS: This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. RESULTS: We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48-73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14-24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR, 1.02 and 1.56, respectively; P < .03), with significant interaction with sickness severity status. CONCLUSIONS: Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association (167,(171)(172)(173).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [171]
In the citing paper
“Antibiotics are subject to changes in PK/PD parameters in sepsis and septic shock where resultant concentrations may be too low risking clinical failure, or too high leading to toxicity (Table 3) [237–239].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [238]
Citations
Cites
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376 · cited 1×
“Various demographic and clinical data were collected including age, sex, height, weight, presence of renal replacement therapy, and measures of organ function and levels of patient sickness severity as described by the APACHE II (Acute Physiology and Chronic Health Evaluation II) score [15] on admission and SOFA (Sequ…”
MethodKumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundHarbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464 · cited 2×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundResultSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414 · cited 1×
“These patients may have augmented renal clearances needing either higher doses or more frequent dosing to overcome increased drug elimination [22, 23].”
BackgroundSelf-citationAntibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408 · cited 2×
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
Background
Cited by
Items 701–800 of 1,000
Wulkersdorfer, B., Bergmann, F., Amann, L. F., Fochtmann‐Frana, A., al Jalali, V., Kurdina, E., Lackner, E., Wicha, S. G., Dorn, C., Schäfer, B., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad368 · Cited by 6
Zhang, X., Wang, Y., Li, S., Xie, F., & Yi, H. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01541-23 · Cited by 6
Chen, Y., Chen, B., Huang, Y., Li, X., Wu, J., Lin, R., Chen, M., Liu, M.-B., Qiu, H., & Cheng, Y. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s495279 · Cited by 6
May, F., El-Helali, N., Timsit, J., & Misset, B. (2016) · Critical Care · doi:10.1186/s13054-016-1394-2 · Cited by 6
“Beta-lactams (BL) are the most frequently prescribed antibiotics because of their broad spectrum and low toxicity [2].”
Fuster, Ó., Zapater, P., & Gerónimo‐Pardo, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.903 · Cited by 6
“8-100], and the total amount of acetaminophen administered was 24 [18-35] g per patient.”
BackgroundCarlier, M., Athanasopoulos, A., Borrey, D., Colin, P. J., COTTON, F. J., Denooz, R., Neels, H. M., Spriet, I., Ghys, T., Verstraete, A., et al. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000467 · Cited by 6
Augmented renal clearance: Much more is better?
Tomasa-Irriguible, T. M. (2018) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2018.07.006 · Cited by 6
“In the case of sepsis, the inadequate dose of an antibiotic (AB) worsens prognosis and increases the generation of resistances.(1)”
BackgroundPharmacokinetic Model for Cefuroxime Dosing during Cardiac Surgery under Cardiopulmonary Bypass
Lanoiselée, J., Zufferey, P. J., Hodin, S., Tamisier, N., Gergelé, L., Palao, J.-C., Campisi, S., Molliex, S. B., Morel, J., Delavenne, X., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01687-20 · Cited by 6
“Data suggest that the longer time above the MIC, the better the outcome in infected patients (25).”
BackgroundWeinelt, F. A., Stegemann, M. S., Theloe, A., Pfäfflin, F., Achterberg, S., Schmitt, L., Huisinga, W., Michelet, R., Hennig, S., & Kloft, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122128 · Cited by 6
Minotti, C., Barbieri, E., Doni, D., Impieri, C., Giaquinto, C., & Donà, D. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.868513 · Cited by 6
Corte, T. D., Verhaeghe, J., Dhaese, S. A. M., Vooren, S. V., Boelens, J., Verstraete, A., Stove, V. V., Ongenae, F., Bus, L. D., Depuydt, P. O., et al. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01129-6 · Cited by 6
“Despite this progress, some studies still indicate that a large proportion of patients is sub optimally treated when considering relevant pharmacokinetic/pharmacodynamic (PK/PD) targets [3].”
BackgroundCorreia, P. A., Launay, M., Balluet, R., Gergelé, L., Gauthier, V., Morel, J., Beuret, P., Mariat, C., Thiéry, G., & Périnel, S. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad339 · Cited by 7
Vandecasteele, S. J., Bastos, A. C. M., Capron, A., Spinewine, A., Tulkens, P. M., & Françoise Van Bambeke, A. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.09.005 · Cited by 6
Martín‐Loeches, I., Metersky, M. L., Kalil, A. C., Pezzani, M. D., & Torres, A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1857730 · Cited by 6
“The DALI study, a point prevalence pharmacokinetic study across different ICUs worldwide, showed that 20% and 40% of the ICU population receiving beta lactams did not achieve free antibiotic concentrations above their pathogen’s MIC during 50% and 100% of the dosing interval [33].”
BackgroundSelf-citationTherapeutisches Drug Monitoring (TDM) in der antiinfektiven Therapie – von der Theorie zur Praxis
Brinkmann, A., Röhr, A. C., Richter, D., Chiriac, U., & Frey, O. R. (2021) · Krankenhaushygiene up2date · doi:10.1055/a-1173-5813 · Cited by 6
al Jalali, V., Wölfl‐Duchek, M., Taubert, M., Matzneller, P., Lackner, E., Dorn, C., Kratzer, A., Wulkersdorfer, B., Österreicher, Z. A., & Zeitlinger, M. A. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab166 · Cited by 6
Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay
Meng, Q., Wang, Y., Long, Y., Yue, A., Mecklenburg, M., Tian, S., Fu, Y., Yao, X., Liu, J., Song, D., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10091110 · Cited by 6
“This is especially important when treating critically ill patients where administration of standard antibiotic dosages sometimes results in subtherapeutic antibiotic blood concentration levels that adversely affect treatment outcomes [1,2].”
BackgroundJang, S. M., Lewis, S. J., & Rhie, S. J. (2022) · Journal of Critical Care · doi:10.1016/j.jcrc.2022.154172 · Cited by 6
Seo, H., Kim, Y. K., Park, S., Kim, H. I., & Lee, D. H. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0087 · Cited by 7
“org proposed in recent studies to achieve improved microbiological and clinical outcomes in critically ill patients [21-26].”
Toxicidad antibacterianos: farmacocinética-farmacodinamia: prevención y manejo
Palavecino, C. M. (2014) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(14)70061-6 · Cited by 6
“Recientemente fue publicado un estudio realizado a través de 68 UCIs, donde se muestra que la mayoría de los pacientes están por debajo del objetivo PK-PD, sugiriendo a los médicos de UCI ajustar las estrategias de dosificación, ya que con la significativa variabilidad observada, no es posible asegurar una adecuada ex…”
BackgroundA Review of Therapeutic Drug Monitoring of Beta-Lactams
Paytes, A., Frens, J. J., & McCormick, R. (2024) · Current Infectious Disease Reports · doi:10.1007/s11908-024-00832-0 · Cited by 5
Chai, M. G., Roberts, N. A., Dobbins, C., Roberts, J. A., & Cotta, M. O. (2024) · Applied Clinical Informatics · doi:10.1055/s-0044-1786978 · Cited by 5
Self-citationSoriano, À., Paterson, D. L., Thalhammer, F., Kluge, S., Viale, P., Akrich, B., Allen, M., Wirbel, S., Watanabe, A. H., Yücel, E., et al. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.116737 · Cited by 5
König, C., Kuti, J. L., & Fratoni, A. J. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70029 · Cited by 5
Varela-Rey, I., Martínez-Guitián, M., Hermelo-Vidal, G., Bandín‐Vilar, E., Novo‐Veleiro, I., Varela-García, P. M., Zarra‐Ferro, I., González‐Barcia, M., Mondelo‐García, C., & Fernández‐Ferreiro, A. (2025) · Antibiotics · doi:10.3390/antibiotics14060613 · Cited by 5
Barreto, E. F., Chang, J. H. T., Rule, A. D., Mara, K. C., Fogelson, L. A., Paul, J., Jannetto, P. J., Athreya, A. P., Scheetz, M. H., Gajic, O., et al. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107586 · Cited by 5
Antimicrobial dosing considerations in critically ill patients with acute kidney injury: A review
Tee, C., Ngai, M., & See, K. C. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i3.102667 · Cited by 5
Giner, S. G., ALEMANY, A. L., Porta-Oltra, B., Llopis-Salvia, P., Martí, M. C., & Martínez‐Gómez, M. A. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimc.2022.07.008 · Cited by 5
Liu, T., Chen, L., Yu, P., Li, Q., & Lou, J. (2022) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmac086 · Cited by 5
Bellouard, R., Rambaud, A., Delaunay, C., Dailly, É., Lecomte, R., Deschanvres, C., Leroy, A., Boutoille, D., Turnier, P. L., Grégoire, M., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad030 · Cited by 5
Roberts, J. A., Sime, F. B., Lipman, J., Hernández-Mitre, M. P., Baptista, J. P., Brüggemann, R. J. M., Darvall, J. N., Waele, J. J. D., Dimοpoulos, G., Lefrant, J., et al. (2023) · Critical Care and Resuscitation · doi:10.1016/j.ccrj.2023.04.002 · Cited by 5
Self-citationRazazi, K., Berti, E., Cecchini, J., Carteaux, G., Habibi, A., Bartolucci, P., Arrestier, R., Gendreau, S., de Prost, N., Lesne-Hulin, A., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302298 · Cited by 5
Rentsch, K., Khanna, N., Halbeisen, D., & Osthoff, M. F. (2024) · Antibiotics · doi:10.3390/antibiotics13100970 · Cited by 5
Roberts, J. A., Heffernan, A. J., Chai, M. G., Harris, P. N. A., Legg, A., Farkas, A., Laupland, K. B., Dhanani, J., Fourie, C., Murray, L., et al. (2024) · CMI Communications · doi:10.1016/j.cmicom.2024.105051 · Cited by 6
Self-citationReeder, J. A., Creech, C. B., Nation, R. L., Gu, K., Nalbant, D., Wu, N., Jimenez‐Truque, N., Fissell, W. H., Rolsma, S. L., Fishbane, N., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6161 · Cited by 5
Marko, B., Palmowski, L., Nowak, H., Witowski, A., Koos, B., Rump, K., Bergmann, L., Bandow, J. E., Eisenacher, M., Günther, P. S., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086094 · Cited by 5
Geremia, N., Bella, S. D., Lovecchio, A., Angelini, J., D’Avolio, A., Luzzati, R., Mearelli, F., Principe, L., & Oliva, A. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2448727 · Cited by 5
Dillon, R. C., Witcher, R., Cies, J. J., Moore, W. S., & Chopra, A. (2017) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-22.1.60 · Cited by 5
La prothèse de hanche infectée : le point de vue du médecin
Coiffier, G., & Bart, G. (2019) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2019.05.002 · Cited by 5
A narrative review on antimicrobial therapy in septic shock: updates and controversies
Ling, L., Joynt, G. M., & Lipman, J. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000954 · Cited by 5
“com lactam antibiotics do not receive adequate doses of antimicrobials [47].”
BackgroundSelf-citationSmit, C., Sen, S., von Dach, E., Karmime, A., Lescuyer, P., Tonoli, D., Bielicki, J. A., Huttner, A., & Pfister, M. (2022) · Antibiotics · doi:10.3390/antibiotics11091190 · Cited by 5
“In these cases, an increased dose might be necessary, in line with earlier observations [10,25,26].”
ResultIshikawa, K., Shibutani, K., Kawai, F., Ota, E., Takahashi, O., & Mori, N. (2023) · Antibiotics · doi:10.3390/antibiotics12061024 · Cited by 5
“Recent studies have suggested that standard dosage regimens of bolus infusion for beta-lactam antibiotics may not be ideal for achieving pharmacokinetic/pharmacodynamic (PK/PD) targets in patients [7].”
BackgroundMeropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
Gan, Y., Meng, X., Lei, N., Yu, H. B., Zeng, Q., & Huang, Q. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s408572 · Cited by 5
El‐Haffaf, I., Marsot, A., Hachemi, D., Pesout, T., Williams, V., Smith, M.-A., Albert, M., & Williamson, D. R. (2024) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-023-02689-8 · Cited by 5
Therapeutisches Drug-Monitoring in der antiinfektiven Therapie
Brinkmann, A., Röhr, A. C., Krüger, W. A., & Frey, O. R. (2017) · Krankenhaushygiene up2date · doi:10.1055/s-0042-123738 · Cited by 5
“Promotion 1995 über Pharmakokinetik von Ciprofloxacin und dessen Einfluss auf die mikrobielle Flora im Darm (LMU München) und Habilitation 2004 mit dem Thema: „Strategien zur Optimierung der antimikrobiellen Therapie bei kritisch kranken Patienten“ (Universität Tübingen).”
BackgroundInfluentialOptimal and responsible use of antibiotics
Depuydt, P. O., & Waele, J. J. D. (2019) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000645 · Cited by 5
“This impacts outcomes, with improved outcome reported in patients with higher antibiotic concentrations [27].”
BackgroundLonsdale, D., Lipman, J., Livermore, A., McWhinney, B. C., Ungerer, J. P. J., & Roberts, J. A. (2019) · Chemotherapy · doi:10.1159/000505057 · Cited by 5
Self-citationBöhle, T., Georgi, U., Hughes, D. F., Hauser, O., Stamminger, G., & Pohlers, D. (2020) · Journal of Laboratory Medicine · doi:10.1515/labmed-2020-0052 · Cited by 5
Meropenem serum concentrations in intensive care patients: a retrospective analysis
Ďuricová, J., Kacířová, I., & Brozmanová, H. (2020) · Česká a slovenská farmacie · doi:10.36290/csf.2020.032 · Cited by 5
The future of acute and emergency care
Newcombe, V., Coats, T., Dark, P. M., Gordon, A. C., Harris, S. K., McAuley, D. F., Menon, D. K., Price, S., Puthucheary, Z., & Singer, M. (2021) · Future Healthcare Journal · doi:10.7861/fhj.2021-0097 · Cited by 5
Self-citationDosing strategies of imipenem in neonates based on pharmacometric modelling and simulation
Dao, K., Fuchs, A., André, P., Giannoni, É., Decosterd, L. A., Marchetti, O., Asner, S. A., Pfister, M., Widmer, N., Buclin, T., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab394 · Cited by 5
Principles of Geriatric Pharmacotherapy
Devlin, J. W., & Barletta, J. F. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316676325.004 · Cited by 5
Mazlan, M. Z., Ghazali, A. G., Omar, M., Yaacob, N. M., Mohamad, N. A. N., Hassan, M. H., & Shukeri, W. F. W. M. (2024) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2024.31.1.7 · Cited by 6
“Roberts et al. (42) found there was an association increasing 100% ƒT > MIC ratio (OR = 1.53; P = 0.03) and positive clinical outcome.”
BackgroundInfluentialAntibiotic administration in the critically ill - in need of intensive care!
Mer, M., & Lipman, J. (2015) · South African Medical Journal · doi:10.7196/samj.9665 · Cited by 5
Self-citationCrass, R. L., Williams, P. G., & Roberts, J. A. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.12.008 · Cited by 5
Self-citationSpriet, I., & Waele, J. J. D. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202210-2000ed · Cited by 5
“Antimicrobial dose optimization is trending in intensive care medicine; large variability in antimicrobial exposure has repeatedly been demonstrated, potentially leading to underdosing and therapeutic failure or to overdosing and toxicity (2).”
BackgroundMu, Z., Wang, J., & Mu, E. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102634 · Cited by 4
Truong, A. Q., Smeets, T. J. L., Terrier, J. E., Li, L., Co, D. X., Strojil, J., Preijers, T., Koch, B. C. P., Huttner, A., & Sassen, S. D. T. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.05.005 · Cited by 4
Chiriac, U., Muenchow, M., Roehr, A. C., Frey, O. R., Frey, A. T., Frisch, D., Gaasch, M., Weigand, M. A., Wicha, S. G., & Brinkmann, A. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.04.010 · Cited by 4
Artificial intelligence in medication management and drug dosing in critical care
Azarvash, N., Patel, D. A., Quickfall, D., Hambrick, H. R., KASHANI, K. B., & Tootooni, M. S. (2025) · Journal of Translational Critical Care Medicine · doi:10.1097/jtccm-d-25-00024 · Cited by 4
Pauw, H. S., Schwarz, R. B., Beij, A., Sieswerda, E., Voermans, R. P., van Santvoort, H. C., & van den Berg, F. F. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag092 · Cited by 4
Hill, D. M., Yang, B., Laizure, S. C., Boucher, B. A., Swanson, J. M., Wood, G. C., Hickerson, W. L., Liu, X., & Velamuri, S. R. (2023) · Journal of Burn Care & Research · doi:10.1093/jbcr/irad134 · Cited by 4
The OPAT opportunity for beta-lactam individualization
Childs‐Kean, L. M., Rivera, C. G., Venugopalan, V., Johnson, M. J., & Barreto, E. F. (2024) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2024.367 · Cited by 4
Wu, J., Wang, C., Zhang, R., Du, P., Wang, Y., Wu, P., Chen, X., Huang, Y., Jia, Y., & Shen, J. (2024) · Biomedical Chromatography · doi:10.1002/bmc.5964 · Cited by 4
Chen, Y., Li, W., Liu, X., Chen, Y., Zhang, J., Li, N., & Yang, L. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107356 · Cited by 4
SERS-Driven Ceftriaxone Detection in Blood Plasma: A Protein Precipitation Approach
Dwivedi, A., Ryabchykov, O., Liu, C., Farnesi, E., Schmidt, M., Bocklitz, T. W., Popp, J., & Cialla‐May, D. (2024) · Chemosensors · doi:10.3390/chemosensors12100213 · Cited by 5
A retrospective cohort analysis of factors influencing continuous antibiotic therapy with ampicillin
Weber, L., Moerer, O., Wieditz, J., Winkler, M. S., Scheithauer, S., & Stephani, C. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123168 · Cited by 4
Kumta, N., Heffernan, A. J., Cotta, M. O., Liu, X., Parker, S. L., Wallis, S. C., Livermore, A., Starr, T., Wong, W., Joynt, G. M., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00601-24 · Cited by 4
“Aggressive fluid resuscitation and enhanced capillary permeability in sepsis can increase V d of hydrophilic drugs such as piperacillin and tazobactam (34, 35).”
Self-citationKoenig, C., McGrath, C. P., Roenfanz, H. F., Shen, Y., Monogue, M. L., Nicolau, D. P., & Kuti, J. L. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf199 · Cited by 4
Dosing of Ertapenem in an Extreme Obesity: A Case Report of 250 kg Patient
Lass, J., Tamme, K., Kipper, K., & Starkopf, J. (2017) · Case Reports in Critical Care · doi:10.1155/2017/5310768 · Cited by 4
Pea, F. (2022) · Frontiers in Antibiotics · doi:10.3389/frabi.2022.1016760 · Cited by 4
“The sepsis-related tissue capillary leakage coupled with the fluid load frontiersin.org needed for maintaining volemia, which may cause an increase in volume of distribution of antibiotics (Roberts et al., 2012; Roberts et al., 2014).”
BackgroundInfluentialClosed-loop control of continuous piperacillin delivery: An in silico study
Herrero, P., Wilson, R. C., Armiger, R., Roberts, J. A., Holmes, A. H., Georgiou, P., & Rawson, T. M. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1015389 · Cited by 4
Self-citationRamadan, O., Schatz, L. M., van den Heuvel, I. A., Masjosthusmann, K., Groll, A. H., & Hempel, G. (2023) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001105 · Cited by 4
Toxicity consideration of antibiotics
Ali, S. S., Ali, A. M. M., Elsamahy, T., Okasha, K. M., & Sun, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95388-7.00008-5 · Cited by 4
Dräger, S., Ewoldt, T. M. J., Abdulla, A., Rietdijk, W. J. R., Verkaik, N. J., Ramakers, C. R. B., de Jong, E., Osthoff, M. F., Koch, B. C. P., & Endeman, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020270 · Cited by 4
Verhaeghe, J., Corte, T. D., Waele, J. J. D., Ongenae, F., & Hoecke, S. V. (2024) · International Conference on Medical and Health Informatics (ICMHI) · doi:10.1145/3673971.3673982 · Cited by 4
Horstink, M. M. B., Geel, D. R., den Uil, C. A., Deetman, P. E., Endeman, H., Abdulla, A., Bosch, T. M., Rietdijk, W. J. R., Thielen, F. W. F., Haringman, J. J., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10747-3 · Cited by 4
Cies, J. J., Moore, W. S., Conley, S. B., SHEA, P. A., Enache, A., & Chopra, A. (2017) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-22.1.69 · Cited by 4
β-lactam prolonged infusion: it's time to implement!
Paul, M., & Theuretzbacher, U. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30614-x · Cited by 4
Almulhim, A., Al-Dahneen, B. A., & Alsowaida, Y. S. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00310-9 · Cited by 4
Effect of Obesity on Clinical Outcomes of Patients Treated With Cefepime
Morrison, A. R., Loper, J. T., Barber, K. E., Stover, K. R., & Wagner, J. L. (2020) · Journal of Pharmacy Technology · doi:10.1177/8755122520967398 · Cited by 4
Hurley, J. C., & Brownridge, D. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab016 · Cited by 4
Cheng, V., Abdul-Aziz, M. H., & Roberts, J. A. (2021) · Current Infectious Disease Reports · doi:10.1007/s11908-021-00757-y · Cited by 4
Self-citationWiniszewski, H., Despres, C., Puyraveau, M., Lagoutte‐Renosi, J., Montange, D., Besch, G., Pili‐Floury, S., Chaignat, C., Labro, G., Vettoretti, L., et al. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.10.023 · Cited by 4
Sappington, P. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44942-7.00097-2 · Cited by 4
Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children
Wang, Y., Sun, D., Yan, M., Wu, S., Li, X., Li, S., Wang, J., Gao, L., Xu, H., & Tuo, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051033 · Cited by 4
“On the basis of balancing maximum efficacy with minimum toxicity and reducing drug resistance, the goal of simulation optimization is that more than 90% of patients have a free drug concentration above the MIC for a time greater than 50% of the dosing interval [15].”
BackgroundGuillamet, C. V., Burnham, J. P., Pérez, M., Kollef, M. H., Manthous, C. A., & Jeffe, D. B. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.389 · Cited by 4
Diffusion of amoxicillin into heart valves from infective endocarditis patients
Lalanne, S., Guérin, F., Flecher, E. M., Cattoir, V., Nesseler, N., Revest, M., & Verdier, M. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac379 · Cited by 4
In silico evaluation of a beta‐lactam dosing guideline among adults with serious infections
Williams, P. G., Cotta, M. O., Abdul-Aziz, M. H., Wilks, K. M., Farkas, A., & Roberts, J. A. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2753 · Cited by 4
“6 Nevertheless, the majority of guideline-based dosing simulations still did not achieve a target PTA (≥90”
BackgroundMethodResultInfluentialSelf-citationJoynt, G. M., Ling, L., Wong, W., & Lipman, J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2194629 · Cited by 5
“clinical efficacy, and minimization of emergence of resistance [15,35,36].”
BackgroundSelf-citationRamos, J. R., Villarreal, E., Gordón, M., Martin-Cerezula, M., Porcar, M. J. B., Marqués, M. R., Poveda, J. L., Castellanos-Ortega, Á., & Ramírez, P. (2017) · Blood Purification · doi:10.1159/000478969 · Cited by 4
Carrié, C., Butruille, J., Maingault, S., Lannou, A., Dubuisson, V., Petit, L., Biais, M., & Breilh, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091191 · Cited by 3
Charoenwong, K., Wacharachaisurapol, N., Sukkummee, W., Sophonphan, J., Suchartlikitwong, P., Chatsuwan, T., Anugulruengkitt, S., & Puthanakit, T. (2024) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004582 · Cited by 3
Thériault, E., Benali, M., Starnino, S., Blain, H., Goettel, N., Beloin-Jubinville, B., Marsot, A., & Lamontagne, F. (2024) · Critical Care Research and Practice · doi:10.1155/2024/9757792 · Cited by 3
Wang, C., Luo, B., Liu, W., Chen, J., Chen, H., Ma, J., Song, X., Ji, X., Cao, A., Bai, Y., et al. (2024) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2024.11.001 · Cited by 3
Urinary Biomarkers and Attainment of Cefepime Therapeutic Targets in Critically Ill Children
Downes, K. J., Sharova, A. P., Amajor, V., Gianchetti, L., Himebauch, A. S., Fitzgerald, J. C., & Zuppa, A. F. (2025) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004784 · Cited by 3
Laporte-Amargós, J., Ulldemolins, M., Hernández-Mitre, M. P., Roberts, J. A., Rigo-Bonnin, R. F., Carmona-Torre, F., Huguet, M., Puerta‐Alcalde, P., Arnán, M., del Pozo, J. L., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01253-25 · Cited by 3
Self-citationLiao, J., Li, C., Liu, J., Wu, W., Huang, X., Mao, Y., & LiXia, L. I. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107697 · Cited by 3
Pharmacists in Interprofessional Critical Care
Barletta, J. F., & Dzierba, A. L. (2026) · Critical Care Clinics · doi:10.1016/j.ccc.2025.11.002 · Cited by 3
Metadata
- Authors
- Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Starr, T., Wallis, S. C., Lipman, J., Study, D., Roberts, J. A., Lipman, J., Starr, T., Wallis, S. C., Paul, S. K., Margarit Ribas, A., De Waele, J. J., De Crop, L., Spapen, H., Wauters, J., Dugernier, T., Jorens, P., Dapper, I., De Backer, D., Taccone, F. S., Rello, J., Ruano, L., Afonso, E., Alvarez-Lerma, F., Gracia-Arnillas, M. P., Fernandez, F., Feijoo, N., Bardolet, N., Rovira, A., Garro, P., Colon, D., Castillo, C., Fernado, J., Lopez, M. J., Fernandez, J. L., Arribas, A. M., Teja, J. L., Ots, E., Carlos Montejo, J., Catalan, M., Prieto, I., Gonzalo, G., Galvan, B., Blasco, M. A., Meyer, E., Del Nogal, F., Vidaur, L., Sebastian, R., Garde, P. M., Martin Velasco, M. D. M., Zaragoza Crespo, R., Esperatti, M., Torres, A., Montravers, P., Baldesi, O., Dupont, H., Mahjoub, Y., Lasocki, S., Constantin, J. M., Payen, J. F., Martin, C., Albanese, J., Malledant, Y., Pottecher, J., Lefrant, J.-Y., Jaber, S., Joannes-Boyau, O., Orban, C., Ostermann, M., McKenzie, C., Berry, W., Smith, J., Lei, K., Rubulotta, F., Gordon, A., Brett, S., Stotz, M., Templeton, M., Rhodes, A., Ebm, C., Moran, C., Kaukonen, K.-M., Pettila, V., Dimopoulos, G., Koulenti, D., Xristodoulou, A., Theodorou, V., Kouliatsis, G., Sertaridou, E., Anthopoulos, G., Choutas, G., Rantis, T., Karatzas, S., Balla, M., Papanikolaou, M., Myrianthefs, P., Gavala, A., Fildisis, G., Koutsoukou, A., Kyriakopoulou, M., Petrochilou, K., Kompoti, M., Michalia, M., Clouva-Molyvdas, F.-M., Gkiokas, G., Nikolakopoulos, F., Psychogiou, V., Malliotakis, P., Akoumianaki, E., Lilitsis, E., Koulouras, V., Nakos, G., Kalogirou, M., Komnos, A., Zafeiridis, T., Chaintoutis, C., Arvaniti, K., Matamis, D., Chaintoutis, C., Kydona, C., Gritsi-Gerogianni, N., Giasnetsova, T., Giannakou, M., Soultati, I., Chytas, I., Antoniadou, E., Antipa, E., Lathyris, D., Koukoubani, T., Paraforou, T., Spiropoulou, K., Bekos, V., Spring, A., Kalatzi, T., Nikolaou, H., Laskou, M., Strouvalis, I., Aloizos, S., Kapogiannis, S., Soldatou, O., Bassetti, M., Adembri, C., Villa, G., Giarratano, A., Maurizio Raineri, S., Cortegiani, A., Montalto, F., Strano, M. T., Ranieri, V. M., Sandroni, C., De Pascale, G., Molin, A., Pelosi, P., Montagnani, L., Urbino, R., Mastromauro, I., De Rosa, F. G., Ranieri, V. M., Cardoso, T., Afonso, S., Goncalves-Pereira, J., Baptista, J. P., Akova, M., & Ozveren, A.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- The University of Queensland (AU)
- Ghent University Hospital (BE)
- Centre Hospitalier Universitaire de Nîmes (FR)
- University General Hospital Attikon (GR)
- Sorbonne Paris Cité (FR)
- St George's, University of London (GB)
- University of Palermo (IT)
- University of Genoa (IT)
- Hacettepe University (TR)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-14
- Volume
- 58
- Issue
- 8
- Pages
- 1072-1083
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101416655
- Cited by
- 1,090
- References
- 31
- Citations by year
- 2026: 75 · 2025: 98 · 2024: 83 · 2023: 125 · 2022: 115 · 2021: 125 · 2020: 86 · 2019: 84 · 2018: 69 · 2017: 71 · 2016: 66 · 2015: 57 · 2014: 34
- FWCI
- 55.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- HAL (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NIHR/CS/009/007)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- beta-lactam antibiotics, antibiotic dosing, critically ill patients, intensive care unit, pharmacokinetics, pharmacodynamics, free drug concentration, time above MIC, patient outcomes
- MeSH terms
- Aged, Anti-Bacterial Agents, Bacterial Infections, Blood Chemical Analysis, Female, Humans, Intensive Care Units, International Cooperation, Male, Microbial Sensitivity Tests, Middle Aged, Prospective Studies, Models, Statistical, Critical Illness, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.